Here are four things to know.
- The Saint Paul, Minn.-based drugmaker received seven reports of lost telemetry and heart pacing output from the pacemakers, according to the report. The problems surfaced 29 to 37 months after the device was implanted.
- Out of the 1,423 devices implanted in patients across the globe, 1,397 are still in service, representing a potential risk to patients, St. Jude said.
- The company issued a letter to physicians, instructing them not to implant any more Nanostim pacemakers into patients. Any devices in stock should be returned to the company. St. Jude recommends device replacement for any patient implanted with the device.
- According to St. Jude, there have been no reports of injury related to the device malfunction.
More articles on supply chain:
EpiPen price hikes cost DOD millions
Kits for care: How global sourcing helped Northside Hospital boost patient comfort
FDA approves Medtronic’s larger aortic valve replacement system
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
